CTChow Wei Too

Chow Wei Too

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chow Wei Too has a total of 209 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Percutaneous Ultrasound-Guided Ablation of Implanted Parathyroid Glands for Recurrent Hyperparathyroidism After Total Parathyroidectomy

    by Guanqi Hang, Jiunn Wong, Sum Leong, Julia Andres, Weiyong Lee, Chow Wei Too

    Purpose: Tertiary hyperparathyroidism is a frequent complication of end-stage kidney disease that may require parathyroidectomy when medical therapy fails. Recurrent hyperparathyroidism may occur after total parathyroidectomy with autotransplantation. This study assessed the safety, feasibility, and efficacy of percutaneous ultrasound-guided ablation for implanted parathyroid glands in patients with recurrent disease after total parathyroidectomy with autotransplantation. Materials and Methods: Eleven patients with recurrent hyperparathyroidism following total parathyroidectomy with autotransplantation who underwent percutaneous ultrasound-guided ablation were retrospectively reviewed. Pre- and post-procedure serum intact parathyroid hormone, calcium, phosphate, and alkaline phosphatase levels were extracted from electronic medical records and analyzed. Ablation modalities used in the study included radiofrequency ablation, microwave ablation, and cryoablation. Procedure-related complications were recorded. Patients were followed for 12 months with serial biomarker monitoring. Technical success was defined as ≥80% ablation of implanted parathyroid glands, and clinical success as meeting at least two of the following: (1) >50% intact parathyroid hormone reduction, (2) correction of hypercalcemia, (3) discontinuation of calcimimetic therapy. Results: Technical success was achieved in 10 of 11 (90.9%) patients; one patient had incomplete ablation due to proximity of the gland to the skin. Among technically successful cases, all (100%) achieved clinical success, showing marked decreases in intact parathyroid hormone, normalization of calcium and phosphate, and reduced calcimimetic use. Transient hypocalcemia occurred in six patients, five requiring intravenous calcium replacement. No long-term complications were observed. Conclusions: Percutaneous ultrasound-guided ablation of implanted parathyroid glands is a safe and effective option for managing recurrent hyperparathyroidism, offering a viable alternative to surgery.

  • Feasibility of Robot-Assisted CT-Guided Interventions Compared with Conventional Technique: A Prospective, Randomized, Clinical Trial

    by Takafumi Sato, Tatsuya Kawai, Junichi Takikawa, Keita Nakayama, Shota Ohba, Masashi Shimohira, Kengo Ohta, Kazushi Suzuki, Shinji Kato, Yoshinao Ojio, et al.


  • Open Access

    Access and Reimbursement for Artificial Intelligence in Radiology: A Singapore Perspective

    by Francis Cho Hao Ho, Charles Xian Yang Goh, Tze Chwan Lim, Chow Wei Too, Cher Heng Tan

    Ho FC, et al. Korean J Radiol. 2025 Dec;26(12):1117-1119. https://doi.org/10.3348/kjr.2025.1498


  • Open Access

    The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation

    by Kaina Chen, Aaron K.T. Tong, Fiona N.N. Moe, David C.E. Ng, Richard H.G. Lo, Apoorva Gogna, Sean X. Yan, Sue Ping Thang, Kelvin S.H. Loke, Nanda Karaddi Venkatanarasimha, et al.

    Introduction: Transarterial radioembolisation (RE) using yttrium-90 (Y-90) microspheres is a widely used locoregional therapy for a broad spectrum of hepatocellular carcinoma (HCC) given its favourable safety profile. We evaluated the real-world outcomes of unresectable HCC treated with resin Y-90 RE and the relationship between tumour absorbed dose and subsequent curative therapy with survival. Methods: Included were consecutive patients treated with Y-90 resin microspheres RE for unresectable HCC between January 2008 and May 2019 at the National Cancer Centre Singapore/Singapore General Hospital. The outcomes were stratified by tumour burden, distribution, presence of portal vein invasion (PVI) and liver function to improve prognostication. Results: The median overall survival (OS) evaluated on 413 included patients was 20.9 months (95% CI: 18.2–24.0). More than half of the patients (214/413, 51.8%) had HCC beyond up-to-seven criteria, and 37.3% had portal vein invasion (154/413, 37.3%). Majority (71.7%) had dosimetry calculated based on the partition model. Patients who received ≥150 Gy to tumour had significantly better outcomes (OS 32.2 months, 95% CI: 18.3–46.4) than those who did not (OS 17.5 months, 95% CI: 13.7–22.7, p < 0.001). Seventy patients (17%) received curative therapies after tumour was downstaged by Y-90 RE and had better OS of 79.7 months (95% CI: 40.4 – NE) compared to those who did not receive curative therapies (OS 17.1 months; 95% CI: 13.5–20.4, p < 0.001). RE-induced liver injury was observed in 5.08% of the patients while 3.2% of the patients had possible radiation pneumonitis but none developed Grade 3–4 toxicity. For HCC without PVI, OS differed significantly with performance status, albumin-bilirubin grade, tumour distribution, and radiation dose; for HCC with PVI, Child-Pugh class and AFP were significant predictors of survival. Conclusions: Treatment outcomes for unresectable HCC using Y-90 RE were favourable. Incorporating tumour burden and distribution improved prognostication. Patients who received tumour absorbed dose above 150 Gy had better OS. Patients who subsequently received curative therapies after being downstaged by Y-90 RE had remarkable clinical outcomes.


  • Open Access

    Contribution and challenges of musculoskeletal radiologists in interventional oncology—Is the cause worth the cost?

    by Jin Rong Tan, Bimal Mayur Kumar Vora, Eu Jin Tan, May San Mak, Chee Yeong Lim, Chow Wei Too, P Chandra Mohan


  • Artificial Intelligence–Guided Segmentation and Path Planning Software for Transthoracic Lung Biopsy

    by Chow Wei Too, Khi Yung Fong, Guanqi Hang, Takafumi Sato, Chiaw Qing Nyam, Siang Huei Leong, Ka Wei Ng, Wei Lin Ng, Tatsuya Kawai


  • Open Access

    Training of Radiology Residents in Singapore

    by Francis Cho Hao Ho, Cher Heng Tan, Tze Chwan Lim, Chow Wei Too, Hsien Min Low, Charles Xian Yang Goh

    Ho FC, et al. Korean J Radiol. 2024 Dec;25(12):1036-1038. https://doi.org/10.3348/kjr.2024.1055


  • IR management of portal hypertension complications

    by Apoorva Gogna, Hiang Keat Tan, Chow Wei Too, Jason Chang Pik Eu


  • Open Access

    Targeted Anterior Cervical Epidural Blood Patch in a Patient with Spontaneous Intracranial Hypotension

    by Ravindra Singh Shekhawat, Ming Hui Yong, Si Ying Julienne Keong, Kunihiko Chen, Chow Wei Too, Shahul Hameed

    A 45-year-old male was admitted with severe orthostatic headache secondary to spontaneous intracranial hypotension. He had the site of cerebrospinal fluid (CSF) leakage identified at the anterolateral aspect of the C7-T1 spinal level. He first underwent a conventional posterior-approach cervical epidural blood patch (EBP) which provided immediate relief to the patient's symptoms; however, his symptoms recurred two days later. To better target the anterolateral leakage site, we employed an anterior-approach EBP under computed tomography (CT) guidance. After this attempt, the patient experienced complete relief of his symptoms, and the headache eventually resolved.


  • Open Access

    First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis

    by Khi Yung Fong, Joseph Jonathan Zhao, Rehena Sultana, Joycelyn Jie Xin Lee, Suat Ying Lee, Stephen Lam Chan, Thomas Yau, David Wai Meng Tai, Raghav Sundar, Chow Wei Too

    Introduction: Sorafenib was historically the standard of care for advanced hepatocellular carcinoma (aHCC) until it was superseded by the combination of atezolizumab and bevacizumab. Thereafter, several novel first-line combination therapies have demonstrated favorable outcomes. The efficacies of these treatments in relation to current and previous standards of care are unknown, necessitating an overarching evaluation. Methods: A systematic literature search was conducted on PubMed, EMBASE, Scopus, and the Cochrane Controlled Register of Trials for phase III randomized controlled trials investigating first-line systemic therapies for aHCC. Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) were graphically reconstructed to retrieve individual patient-level data. Derived hazard ratios (HRs) for each study were pooled in a random-effects network meta-analysis (NMA). NMAs were also conducted using study-level HRs for various subgroups, according to viral etiology, Barcelona Clinic Liver Cancer (BCLC) staging, alpha-fetoprotein (AFP) levels, macrovascular invasion, and extrahepatic spread. Treatment strategies were ranked using p scores. Results: Among 4,321 articles identified, 12 trials and 9,589 patients were included for analysis. Only two therapies showed OS benefit over sorafenib: combined anti-programmed-death and anti-VEGF pathway inhibitor monoclonal antibodies (Anti-PD-(L)1/VEGF Ab), including atezolizumab-bevacizumab and sintilimab-bevacizumab biosimilar (HR = 0.63, 95% CI = 0.53–0.76) and tremelimumab-durvalumab (HR = 0.78, 95% CI = 0.66–0.92). Anti-PD-(L)1/VEGF Ab showed OS benefit over all other therapies except tremelimumab-durvalumab. Low heterogeneity (I2 = 0%) and inconsistency (Cochran’s Q = 0.52, p = 0.773) was observed. p scores for OS ranked Anti-PD-(L)1/VEGF Ab as the best treatment in all subgroups, except hepatitis B where atezolizumab-cabozantinib ranked highest for both OS and PFS, as well as nonviral HCC and AFP ≥400 μg/L where tremelimumab-durvalumab ranked highest for OS. Conclusion: This NMA supports Anti-PD-(L)1/VEGF Ab as the first-line therapy for aHCC and demonstrates a comparable benefit for tremelimumab-durvalumab which also extends to certain subgroups. Results of the subgroup analysis may guide treatment according to baseline characteristics, while pending further studies.